Summary of Patient < 3y at Visit 11 (90 months)
|
|
|
- Pierce McDonald
- 5 years ago
- Views:
Transcription
1 Summary of Patient < 3y at 11 (90 months) Clinician Scoring Page Direct online data entry available? Medication 378 Yes BPW 382 Yes Diagnostic Features 383 Yes UPDRS Clinician 388 Yes CISI-PD 397 Yes MoCA 398 No Scans 406 Blood Tests 409 Yes Patient Questionnaires Page PMH 410 PDQ8 412 EQ5D 413 ESS 414 RBD 415 HADS 416 QUIP 417 Constipation 419 SCOPA-AUT 420 UPDRS Patient 423 NMSS 428 PDSS 438 Wearing off 439 Note: MoCA to be done with the patient on paper, and can then be copied to online Page 377
2 Medication Tick here if completed directly online (you can leave the sheet blank) Antiparkinson drugs (mark one or more) L-dopa (including Stalevo) Amantadine Anticholinergic COMT-I Dopamine agonist MAOB-I None Other (specify below) L-Dopa Co-beneldopa Co-careldopa Controlled release (CR) or similar Other (specify below) Leave blank if patient is not on L-dopa. Dispersible Madopar or similar Sinemet or similar Stalevo L-Dopa times per day >7 Number of different times L-dopa is taken daily. Page 378
3 For a guide to L-dopa doses, see V7 Medication form. Tick here if completed directly online (you can leave the sheet blank) Enter the unit dose of L-dopa taken, e.g. Sinemet Plus 1 tab 3x daily is 100 in each of the first 3 boxes. 1st L-dopa 2nd L-dopa 3rd L-dopa 4th L-dopa 5th L-dopa 6th L-dopa 7th L-dopa Additional L-dopa Include irregular doses, estimate an average if necessary. Amantadine times per day any extra unit dose (mg) (amantadine) Anticholinergic (mark one or more) unit dose Trihexyphenidyl (Benzhexol) Procyclidine Other (specify below) mg mg mg times per day times per day times per day COMT-I (ignore Stalevo here) unit dose Entacapone Tolcapone Other (specify below) mg mg mg times per day times per day times per day Page 379
4 Dopamine agonists unit dose Case Tick here if completed directly online (you can leave the sheet blank) Apomorphine intermittent mg times per day Apomorphine pump mg per hour hours per day Bromocriptine Cabergoline Pergolide Pramipexole (Standard or PR) Salt Base mg mg mg mg mg mg times per day times per day times per day times per day times per day times per day (Ignore system rounding for Pramipexole) Ropinirole (Standard or XL) Rotigotine Other (specify below) mg mg mg times per day times per day times per day MAOB-I unit dose Rasagiline Selegiline Zelapar mg mg mg times per day times per day times per day Other (specify below) mg times per day Page 380
5 Tick here if completed directly online (you can leave the sheet blank) Other Medication Record drugs taken, other than direct antiparkinson drugs, below. Include supporting therapy for PD here, e.g. domperidone, etc. How many drugs (other than direct antiparkinson drugs)? >12 Number of different times L-dopa is taken daily. Record additional medications in the Memo field on the website. Name Name drug 1 Name drug 7 Name drug 2 Name drug 8 Name drug 3 Name drug 9 Name drug 4 Name drug 10 Name drug 5 Name drug 11 Name drug 6 drug 12 Page 381
6 Blood Pressure, Pulse, Weight Tick here if completed directly online (you can leave the sheet blank) Enter in your choice of units Page 382
7 Diagnostic Features Tick here if completed directly online (you can leave the sheet blank) (Questions 1-3 are deliberately omitted at this visit) Please note if any of the following are present Page 383
8 Please mark which of the following are correct in this case Tick here if completed directly online (you can leave the sheet blank) Page 384
9 Tick here if completed directly online (you can leave the sheet blank) Page 385
10 Tick here if completed directly online (you can leave the sheet blank) Page 386
11 Tick here if completed directly online (you can leave the sheet blank) Questions 14 and 15 are omitted deliberately Page 387
12 UPDRS Clinician Scoring Tick here if completed directly online (you can leave the sheet blank) Page 388
13 Tick here if completed directly online (you can leave the sheet blank) Page 389
14 Tick here if completed directly online (you can leave the sheet blank) Page 390
15 Tick here if completed directly online (you can leave the sheet blank) Page 391
16 Tick here if completed directly online (you can leave the sheet blank) Page 392
17 Page 393
18 UPDRS 4 - Motor Complications Tick here if completed directly online (you can leave the sheet blank) Page 394
19 Tick here if completed directly online (you can leave the sheet blank) Page 395
20 Tick here if completed directly online (you can leave the sheet blank) Page 396
21 CISI-PD Clinical Impression of Severity Index Please rate the patient for the following items Tick here if completed directly online (you can leave the sheet blank) Page 397
22 MoCA Montreal Cognitive Assessment (Incorporating MMSE) Case 1. Trail. Please draw a line, going from a number to a letter in ascending order. Begin at 1, and draw a line from 1 to A, then to 2 and so on. End at E Text Examiner: tick if correct 2. Cube. Copy this drawing as accurately as you can, in the space below Examiner: tick if correct Page 398
23 3a. Clock. Draw a clock. Put in all the numbers and set the time to 10 past 11 Examiner: tick if correctly done, for circle, numbers, hands 3b. Pentagons. Copy the interlocking pentagons Examiner: tick if correct 4. Naming. Give the name of each animal Examiner: tick if correct Page 399
24 1st TRIAL FACE VELVET CHURCH DAISY RED Examiner: do not record second trial Examiner: tick if correct Examiner: tick if correct Page 400
25 Examiner: tick if correct Page 401
26 dogs were in the room. Page 402
27 Page 403
28 Scoring: One point is given for each item correctly answered. The subject must tell the exact date and the exact place (name of hospital, clinic, office). No points are allocated if subject makes an error of one day for the day and date. The system will calculate the scores for you. Page 404
29 Enter the person s responses here: Page 405
30 Tick here if completed directly online (you can leave the sheet blank) Page 406
31 Tick here if completed directly online (you can leave the sheet blank) Page 407
32 Tick here if completed directly online (you can leave the sheet blank) Page 408
33 Blood Tests Tick here if completed directly online (you can leave the sheet blank) Blood sample for freezer Stick a red barcode with the same ID and centre on to the SST tubes. Spin and pipette the serum into the 3 small freezer tubes and label with a barcode. Do the same for the other SST tube and store the samples at -80 degrees Barcode for SST tubes This shows: ID Centre Page 409
34 please continue Page 410
35 please continue Page 411
36 PDQ 8 please continue Page 412
37 EQ5D Quality of Life 5 Please complete the following questions please continue Page 413
38 ESS Epworth Sleep Scale Page 414 please continue
39 RBD Screening Questionnaire Dream contents mostly match my nocturnal behaviour. Page 415 please continue
40 1. I feel tense or wound up : Most of the time A lot of the time From time to time, occasionally Not at all 2. I still enjoy the things I used to enjoy: Definitely as much Not quite so much Only a little Hardly at all 3. I get a sort of frightened feeling as if something awful is about to happen: Very definitely and quite badly Yes, but not too badly A little, but it doesn t worry me Not at all 4. I can laugh and see the funny side of things: As much as I always could Not quite so much now Definitely not so much now Not at all 5. Worrying thoughts go through my mind: A great deal of the time A lot of the time From time to time, but not too often Only occasionally 6. I feel cheerful: Not at all Not often Sometimes Most of the time 7. I can sit at ease and feel relaxed: Definitely Usually Not often Not at all 8. I feel as if I am slowed down: HADS Hospital Anxiety and Depression Scale Read each item and tick the reply which comes closest to how you have been feeling in the past week. Don't take too long over your replies: your immediate reaction to each item will probably be more accurate than a long thought out response. Nearly all the time Very often Sometimes Not at all 9. I get a sort of frightened feeling like butterflies in the stomach: Not at all Occasionally Quite often Very often 10. I have lost interest in my appearance: Definitely I don t take as I may not take quite I take just as much much care as I should as much care care as ever 11. I feel restless as I have to be on the move: Very much indeed Quite a lot Not very much Not at all 12. I look forward with enjoyment to things: As much as I ever did Rather less than I used to Definitely less than I used to Hardly at all 13. I get sudden feelings of panic: Very often indeed Quite often Not very often Not at all 14. I can enjoy a good book or radio or TV program: Often Sometimes Not often Very seldom Page 416 please continue
41 QUIP Gambling Sex Buying Eating Page 417 please continue
42 Other Behaviours Medication use Page 418 please continue
43 please continue Page 419
44 SCOPA-AUT Page 420 please continue
45 Page 421 please continue
46 Page 422 please continue
47 UPDRS Patient-Completed Sections Page 423 please continue
48 please continue Case Page 424 please continue
49 Page 425 please continue
50 please continue Page 426
51 please continue Page 427
52 NMSS Non-Motor Symptom Scale For all questions on this page, if Severity is answered no, please leave Frequency unmarked. Page 428 please continue
53 For all questions on this page, if Severity is answered no, please leave Frequency unmarked. Page 429 please continue
54 please continue Case For all questions on this page, if Severity is answered no, please leave Frequency unmarked. Page 430 please continue
55 please continue Case For all questions on this page, if Severity is answered no, please leave Frequency unmarked. Page 431 please continue
56 please continue Case For all questions on this page, if Severity is answered no, please leave Frequency unmarked. Page 432 please continue
57 For all questions on this page, if Severity is answered no, please leave Frequency unmarked. please continue Page 433
58 For all questions on this page, if Severity is answered no, please leave Frequency unmarked. Page 434 please continue
59 For all questions on this page, if Severity is answered no, please leave Frequency unmarked. Page 435 please continue
60 For all questions on this page, if Severity is answered no, please leave Frequency unmarked. Page 436 please continue
61 For all questions on this page, if Severity is answered no, please leave Frequency unmarked. Page 437 please continue
62 PDSS PD Sleep Score Page 438
63 Thank you. The questions for this visit are now complete. Page 439
Hospital Anxiety and Depression Scale (HADS)
Hospital Anxiety and Depression Scale (HADS) Questionnaire Supplement to the Study Data Tabulation Model Implementation Guide for Human Clinical Trials Prepared by Business & Decision Life Sciences and
Parkinson s disease. Information for patients and carers. The Leeds Teaching Hospitals NHS Trust
n The Leeds Teaching Hospitals NHS Trust Parkinson s disease Information for patients and carers in partnership with Leeds Community Healthcare NHS Trust The symptoms of Parkinson s appear when the levels
PARKINSON S MEDICATION
PARKINSON S MEDICATION History 1940 50 s Neurosurgeons operated on basal ganglia. Improved symptoms. 12% mortality 1960 s: Researchers identified low levels of dopamine caused Parkinson s leading to development
Appendix 2: Admissions checklists for people with Parkinson s
Appendix 2: Admissions checklists for people with Parkinson s This document is intended to form the basis of a locally developed tool and so it has been built to be amended with relevant local information,
LIST CHANGES IN YOUR MEDICATION OR SUPPLEMENTS INTAKE (add new meds, changes in old meds or meds you stopped taking) Are you taking it?
Date Patient name: LIST YOUR THREE MAIN COMPLAINTS FOR THIS VISIT - - - New med Old med LIST CHANGES IN YOUR MEDICATION OR SUPPLEMENTS INTAKE (add new meds, changes in old meds or meds you stopped taking)
ACUTE MANAGEMENT OF PARKINSON S PATIENTS WHO ARE NIL BY MOUTH (NBM) OR WHO HAVE A COMPROMISED SWALLOW NHS LANARKSHIRE PARKINSON S TEAM
ACUTE MANAGEMENT OF PARKINSON S PATIENTS WHO ARE NIL BY MOUTH (NBM) OR WHO HAVE A COMPROMISED SWALLOW NHS LANARKSHIRE PARKINSON S TEAM 1 CONTENTS: TOPIC PAGE Introduction 3 What should you do when a PD
Best Medical Treatments for Parkinson s disease
Best Medical Treatments for Parkinson s disease Bernadette Schöneburg, M.D. June 20 th, 2015 What is Parkinson s Disease (PD)? Progressive neurologic disorder that results from the loss of specific cells
Increased Prevalence of Post Traumatic Stress Disorder Symptoms in Critical. Care Nurses. On-line supplement
Increased Prevalence of Post Traumatic Stress Disorder Symptoms in Critical Care Nurses On-line supplement Meredith L. Mealer, R.N. April Shelton, R.N. Britt Berg, M.S. Barbara Rothbaum, Ph.D. Marc Moss,
Guidelines for acute treatment of patients with Parkinson s disease including those who are nil by mouth
Index No: MMG48 Guidelines for acute treatment of patients with Parkinson s disease including those who are nil by mouth Version: 2.0 Date ratified: November 2017 Ratified by: (Name of Committee) Name
MANAGEMENT OF PATIENTS WITH PARKINSON S DISEASE WHO ARE NIL BY MOUTH OR WITH A COMPROMISED SWALLOW
MANAGEMENT OF PATIENTS WITH PARKINSON S DISEASE WHO ARE NIL BY MOUTH OR WITH A COMPROMISED SWALLOW Author: Gordon W Duncan Status: Approved Authorised by: Clinical Policy Group Version: 1.0 Review date:
A trial to evaluate an extended rehabilitation service for stroke patients (EXTRAS) PATIENT BASELINE ASSESSMENT
A trial to evaluate an extended rehabilitation service for stroke patients () PATIENT BASELINE ASSESSMENT Version 5: 11 February 2014 Patient Name: Centre Number: date: Assessor (print name): Assessor
Medications used to treat Parkinson s disease
Medications used to treat Parkinson s disease Edwin B. George, M.D., Ph.D. Director of Wayne State University Movement Disorder Clinic University Health Center Neurology Clinic University Health The John
The Fresco Institute for Parkinson's and Movement Disorders
The Fresco Institute for Parkinson's and Movement Disorders Follow Up Patient Questionnaire Name: Date: Accompanied by: Do you smoke? CURRENT PAST NEVER Which neurological symptom bothers you most right
Parkinson s Disease. Gillian Sare
Parkinson s Disease Gillian Sare Outline Reminder about PD Parkinson s disease in the inpatient Surgical patients with PD Patients who cannot swallow End of life care Parkinson s disease PD is the second
Advanced Therapies for Motor Symptoms in PD. Matthew Boyce MD
Advanced Therapies for Motor Symptoms in PD Matthew Boyce MD Medtronic Education Teva Speakers Bureau Acadia Speakers Bureau Disclosures Discuss issues in advanced PD Adjunct therapies to levo-dopa Newer
Clinical Guideline for the management of inpatients with Parkinson s disease
Clinical Guideline for the management of inpatients with Parkinson s disease Introduction: Parkinson s disease (PD) is the second most common neurodegenerative disorder, characterised by bradykinesia,
Parkinson s Well-Being Map TM
Parkinson s Well-Being Map TM Supporting communication of my Parkinson s The Parkinson s Well-Being Map TM has been endorsed by: Developed in partnership with UCB. All rights reserved 0 UCB, Trademarks
New Medicines Committee Briefing July 2011
New Medicines Committee Briefing July 2011 Pramipexole immediate-release (Mirapexin ) and Pramipexole modifiedrelease (Mirapexin prolonged release) for the treatment of Parkinson s Disease Pramipexole
05-Nov-15. Impact of Parkinson s Disease in Australia. The Nature of Parkinson s disease 21st Century
Peter Silburn Professor Clinical Neuroscience University of Queensland Queensland Brain Institute Neurosciences Queensland Impact of in Australia Second most common neurodegenerative disorder Up to 64,000
Optimizing Clinical Communication in Parkinson s Disease:
Optimizing Clinical Communication in Parkinson s Disease:,Strategies for improving communication between you and your neurologist PFNCA Symposium March 25, 2017 Pritha Ghosh, MD Assistant Professor of
Motor Fluctuations Stephen Grill, MD, PHD Parkinson s and Movement Disorders Center of Maryland and Johns Hopkins University
Motor Fluctuations Stephen Grill, MD, PHD Parkinson s and Movement Disorders Center of Maryland and Johns Hopkins University I have no financial interest with any entity producing marketing, re-selling,
Recent Advances in the cause and treatment of Parkinson disease. Anthony Schapira Head of Dept. Clinical Neurosciences UCL Institute of Neurology UCL
Recent Advances in the cause and treatment of Parkinson disease Anthony Schapira Head of Dept. Clinical Neurosciences UCL Institute of Neurology UCL SOME BACKGROUND incidence rate (per 100.000 person years)
Acute management of in-patient Parkinson s Disease patients
Acute management of in-patient Parkinson s Disease patients Contents Pages Introduction and Admission advice 2 Nil by Mouth Guidance 3 5 Complex therapy advice (Apomorphine, DBS, Duodopa) 6 Surgical peri-operative
10th Medicine Review Course st July Prakash Kumar
10th Medicine Review Course 2018 21 st July 2018 Drug Therapy for Parkinson's disease Prakash Kumar National Neuroscience Institute Singapore General Hospital Sengkang General Hospital Singhealth Duke-NUS
An Overview of Parkinson s Medication used in Multiple System Atrophy
Introduction The cause of Parkinson s symptoms The types of Parkinson s drugs used in MSA Finding the best medication Additional medication Drugs to avoid Further information An Overview of Parkinson s
ALLIANCE COMMUNITY HOSPITAL SLEEP DISORDERS CENTER PATIENT QUESTIONNAIRE/HISTORY PLEASE COMPLETE AND BRING WITH YOU ON THE NIGHT OF YOUR TEST.
ALLIANCE COMMUNITY HOSPITAL SLEEP DISORDERS CENTER PATIENT QUESTIONNAIRE/HISTORY PLEASE COMPLETE AND BRING WITH YOU ON THE NIGHT OF YOUR TEST. NAME DATE: HEIGHT: WEIGHT: DOB: SEX: HOME PHONE #: REFERRING
The symptoms of the Parkinson s disease may vary from person to person. The symptoms might include the following:
1 PARKINSON S DISEASE Parkinson's disease is a long term disease related to the central nervous system that mainly affects the motor system, resulting in the loss of dopamine, which helps in producing
parts of the gastrointenstinal tract. At the end of April 2008, it was temporarily withdrawn from the US Market because of problems related to
parts of the gastrointenstinal tract. At the end of April 2008, it was temporarily withdrawn from the US Market because of problems related to crystallization of the drug, which caused unreliable drug
Continuous dopaminergic stimulation
Continuous dopaminergic stimulation Angelo Antonini Milan, Italy GPSRC CNS 172 173 0709 RTG 1 As PD progresses patient mobility becomes increasingly dependent on bioavailability of peripheral levodopa
Management of Parkinson s Disease in Primary and Secondary care for patients with compromised swallow or those patients deemed Nil By Mouth.
Management of Parkinson s Disease in Primary and Secondary care for patients with compromised swallow or those patients deemed Nil By Mouth. To aid the management and treatment of Parkinson s Patients
Parkinson s Disease Medications: Professionals Edition
Parkinson s Disease Clinic and Research Center University of California, San Francisco 505 Parnassus Ave., Rm. 795-M, Box 0114 San Francisco, CA 94143-0114 (415) 476-9276 http://pdcenter.neurology.ucsf.edu
Anticholinergics. COMT* Inhibitors. Dopaminergic Agents. Dopamine Agonists. Combination Product
Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-945-5220 Fax 503-947-1119 Class Update: Parkinson s Drugs Month/Year of Review:
An Overview of Parkinson s Medication used in Multiple System Atrophy
Introduction Cause of Parkinson s symptoms Parkinson s drug use in MSA Finding the best medication Other medication - Interaction Drugs to avoid Further information An Overview of Parkinson s Medication
Pharmacologic Treatment of Parkinson s Disease. Nicholas J. Silvestri, M.D. Assistant Professor of Neurology
+ Pharmacologic Treatment of Parkinson s Disease Nicholas J. Silvestri, M.D. Assistant Professor of Neurology + Overview n Brief review of Parkinson s disease (PD) n Clinical manifestations n Pathophysiology
Literature Scan: Anti-Parkinson s Agents
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
Key Concepts and Issues in Parkinson s Disease in 2016
Key Concepts and Issues in Parkinson s Disease in 2016 Michael Rezak, M.D., Ph.D. Section Chief, Neurosciences Institute Director, Movement Disorders and Neurodegenerative Diseases Center Northwestern
Pharmacologic Treatment of Parkinson s Disease. Nicholas J. Silvestri, M.D. Associate Professor of Neurology
+ Pharmacologic Treatment of Parkinson s Disease Nicholas J. Silvestri, M.D. Associate Professor of Neurology + Disclosures n NO SIGNIFICANT FINANCIAL, GENERAL, OR OBLIGATION INTERESTS TO REPORT + Learning
Delirium: Information for Patients and Families
health information Delirium: Information for Patients and Families 605837 Alberta Health Services, (2016/11) Resources Delirium in the Older Person Family Guide: search delirium at viha.ca Go to myhealth.alberta.ca
Pharmacy Coverage Guidelines are subject to change as new information becomes available.
ZELAPAR (selegiline hydrochloride) orally disintegrating tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific
History Parkinson`s disease. Parkinson's disease was first formally described in 1817 by a London physician named James Parkinson
Parkinsonismm History Parkinson`s disease Parkinson's disease was first formally described in 1817 by a London physician named James Parkinson Definition : Parkinsonism: Parkinsonism is a progressive neurological
Dr Barry Snow. Neurologist Auckland District Health Board
Dr Barry Snow Neurologist Auckland District Health Board Dystonia and Parkinson s disease Barry Snow Gowers 1888: Tetanoid chorea Dystonia a movement disorder characterized by sustained or intermittent
Parkinson's Disease and how you can make a difference with medication
Parkinson's Disease and how you can make a difference with medication Alyson Franks Parkinson's and Movement Disorder Nurse Specialist Royal Hallamshire Hospital No treatment all Complementary Therapy
Novel approaches to the pharmacological treatment of Parkinson s disease. Peter Jenner King s College UK
Novel approaches to the pharmacological treatment of Parkinson s disease Peter Jenner King s College UK Disclosures and Disclaimers Speakers fees and consultancy fees have been received from Britannia
Medication Management & Strategies When the levodopa honeymoon is over
Medication Management & Strategies When the levodopa honeymoon is over Eric J Pappert, MD Parkinson s Disease & Movement Disorders Center Neurology Associates Medication Options in Parkinson s Carbidopa/Levodopa
Department of Pulmonology
epartment of Pulmonology r. ate of ppointment Time ear Patient: Please complete the enclosed questionnaire and bring it with you on the day of your office visit. Please bring all chest x- ray and CT scan
Program Highlights. Michael Pourfar, MD Co-Director, Center for Neuromodulation New York University Langone Medical Center New York, New York
Program Highlights David Swope, MD Associate Professor of Neurology Mount Sinai Health System New York, New York Michael Pourfar, MD Co-Director, Center for Neuromodulation New York University Langone
Evaluation and Management of Parkinson s Disease in the Older Patient
Evaluation and Management of Parkinson s Disease in the Older Patient David A. Hinkle, MD, PhD Comprehensive Movement Disorders Clinic Pittsburgh Institute for Neurodegenerative Diseases University of
Parkinson s disease: diagnosis and current management
n DRUG REVIEW Parkinson s disease: diagnosis and current management Lucy Collins MPhil, Gemma Cummins MRCPI and Roger A Barker PhD, MRCP SPL Treatment for Parkinson s should be tailored to the needs of
Parkinson s Disease Foundation. PD ExpertBriefing: Managing the Motor Symptoms in PD
Parkinson s Disease Foundation PD ExpertBriefing: Managing the Motor Symptoms in PD Led By: Sotirios A. Parashos, M.D. Minneapolis Clinic of Neurology and Struthers Parkinson's Center This session was
Objectives. Emerging Treatments in Parkinson s s Disease. Pathology. As Parkinson s progresses it eventually affects large portions of the brain.
Objectives Emerging Treatments in Parkinson s s Disease 1) Describe recent developments in the therapies for Parkinson s Disease Jeff Kraakevik MD Assistant Professor OHSU/Portland VAMC Parkinson s Center
Psychological Sleep Services Sleep Assessment
Psychological Sleep Services Sleep Assessment Name Date **************************************************** Insomnia Severity Index For each question, please CIRCLE the number that best describes your
Parkinson s Disease Current Treatment Options
Parkinson s Disease Current Treatment Options Daniel Kassicieh, D.O., FAAN Sarasota Neurology, P.A. PD: A Chronic Neurodegenerative Ds. 1 Million in USA Epidemiology 50,000 New Cases per Year Majority
Thinking about advanced parkinson S
Thinking about advanced parkinson S Symptoms and lifestyle 1 This booklet looks at the advanced stage of Parkinson s. Advanced stage means a time when Parkinson s symptoms are more complex and may be having
Treatment of Parkinson s Disease: Present and Future
Treatment of Parkinson s Disease: Present and Future Karen Blindauer, MD Professor of Neurology Director of Movement Disorders Program Medical College of Wisconsin Neuropathology: Loss of Dopamine- Producing
CLINICAL GUIDELINE FOR THE MANAGEMENT OF INPATIENTS WITH PARKINSON S DISEASE
CLINICAL GUIDELINE FOR THE MANAGEMENT OF INPATIENTS WITH PARKINSON S DISEASE 1. Aim/Purpose of this Guideline To assist all doctors and nurses in the care of inpatients with Parkinson s disease. This guideline
Scottish Medicines Consortium
Scottish Medicines Consortium rotigotine 2mg/24 hours, 4mg/24 hours, 6mg/24 hours, 8mg/24 hours transdermal patch (Neupro ) (No: 289/06) Schwarz Pharma Ltd. 7 July 2006 The Scottish Medicines Consortium
Parkinson s disease Therapeutic strategies. Surat Tanprawate, MD Division of Neurology University of Chiang Mai
Parkinson s disease Therapeutic strategies Surat Tanprawate, MD Division of Neurology University of Chiang Mai 1 Scope Modality of treatment Pathophysiology of PD and dopamine metabolism Drugs Are there
Depression & Anxiety. What can I do? What are other possible treatments? What is this? Why does this happen? KEY POINTS
Depression & Anxiety One set of important protectors from depression is friends and family as much as you can, keep yourself active and engaged with others. Exercise, particularly while outside, may help.
*IR2a. What is the longest number of days in a row you ever had when you were very irritable and had some of these other problems most of the day?
07/25/01 NCS2 IRRITABLE DEPRESSION (IR) *IR1 INTRO 1. *IR1 INTRO 2. Other problems that often occur during episodes of feeling irritable or grouchy include things like changes in sleep, appetite, energy,
2-The age at onset of PD is variable, usually between 50 and 80 years, with a mean onset of 55 years (1).
Parkinson Disease 1-Parkinson disease (PD) is a chronic, progressive movement disorder resulting from loss of dopamine from the nigrostriatal tracts in the brain, and is characterized by rigidity, bradykinesia,
Commonly encountered medications and their side effects - what the generalist needs to know
Commonly encountered medications and their side effects - what the generalist needs to know Jeremy Cosgrove Consultant Neurologist Leeds Teaching Hospitals NHS Trust Outline: Parkinson s medications and
7-DAY HAPPINESS CHALLENGE
7-DAY HAPPINESS CHALLENGE Simple science-based actions for a happier life For more information visit www.actionforhappiness.org Can we change how happy we are? Our happiness is affected by Our genes Our
TRANSPARENCY COMMITTEE OPINION. 18 March 2009
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 18 March 2009 REQUIP LP 2 mg extended-release tablet Box of 21 tablets (CIP: 379 214-8) Box of 28 tablets (CIP: 379
Presented by Meagan Koepnick, Josh McDonald, Abby Narayan, Jared Szabo Mentored by Dr. Doorn
Presented by Meagan Koepnick, Josh McDonald, Abby Narayan, Jared Szabo Mentored by Dr. Doorn Objectives What agents do we currently have available and what do we ideally need? What biomarkers exist for
GENERAL BEHAVIOR INVENTORY Self-Report Version Never or Sometimes Often Very Often
GENERAL BEHAVIOR INVENTORY Self-Report Version Here are some questions about behaviors that occur in the general population. Think about how often they occur for you. Using the scale below, select the
What s new for diagnosing and treating Parkinson s Disease?
What s new for diagnosing and treating Parkinson s Disease? Erika Driver-Dunckley, MD Associate Professor of Neurology Program Director Movement Disorders Fellowship Assistant Program Director Neurology
Communicating About OFF Episodes With Your Doctor
Communicating About OFF Episodes With Your Doctor Early in Parkinson s disease (PD), treatment with levodopa and other anti-pd drugs provides continuous benefit. As the disease progresses, however, symptom
DEPARTMENT OF OTOLARYNGOLOGY HNS SLEEP DISORDERS & DIAGNOSTIC CLINIC
EPRTMENT OF OTOLRYNGOLOGY HNS SLEEP ISORERS & IGNOSTIC CLINIC Patient Name: Medical Record # Last First MI ge: ate of Birth: Sex: M F (circle) PHYSICIN INFORMTION Primary Care Physician: Specialty: ddress:
PD: Key Treatment Considerations
PD: Key Treatment Considerations 2018 Management of Neurologic and Neurosurgical Disorders in Daily Practice Elise Anderson MD Medical Co-Director, PBSI Movement Disorders 11/27/2018 1 Outline Treatment
Dr Jim White. Dr Jim White (2005). All rights reserved. Do not reproduce materials in any form without permission.
Dr Jim White Dr Jim White (2005). All rights reserved. Do not reproduce materials in any form without permission. Insomnia 2 How to get a good night s sleep This booklet aims to help you get a good night
INSOMNIA SEVERITY INDEX
Name: Date: INSOMNIA SEVERITY INDEX For each of the items below, please circle the number that most closely corresponds to how you feel. 1. Please rate the CURRENT (i.e. last 2 weeks) severity of your
PDL Class: Parkinson s Drugs
Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-945-5220 Fax 503-947-1119 Class Update: Parkinson s Drugs Month/Year of Review: September 2013 Date of Last Review:
Anxiety- Information and a self-help guide
Anxiety- Information and a self-help guide Anxiety Anxiety can be a very normal and healthy response to stressful situations, such as paying bills or sitting an exam. However, it becomes a problem when
Pharmacological treatment of Parkinson's disease
Pharmacological treatment of Parkinson's disease Joaquim Ferreira, MD, PhD Laboratory of Clinical Pharmacology and Therapeutics Faculty of Medicine University of Lisbon PD PROGRESSION DISABILITY instability
PD ExpertBriefing: Impulsive and Compulsive Behaviors in Parkinson s Disease
PD ExpertBriefing: Impulsive and Compulsive Behaviors in Parkinson s Disease Presented By: Daniel Weintraub, M.D. Associate Professor of Psychiatry, University of Pennsylvania; Parkinson s Disease and
Your Safety System - a User s Guide.
THE WOODHAVEN ANXIETY/STRESS MANAGEMENT PROGRAMME. Your Safety System - a User s Guide. Isabel Clarke and Becky Mallery. Woodhaven Psychological Therapies Service. 1 Your Safety System - a User s Guide.
Guideline for the Management of Parkinson s Disease Medication Trust Reference B26/2017
Guideline for the Management of Parkinson s Disease Medication Trust Reference B26/2017 1. INTRUCTION 1.1 Guideline for the management of Parkinson s Disease Medication in adult patients presenting to
Re-Submission. Scottish Medicines Consortium. rasagiline 1mg tablet (Azilect ) (No. 255/06) Lundbeck Ltd / Teva Pharmaceuticals Ltd.
Scottish Medicines Consortium Re-Submission rasagiline 1mg tablet (Azilect ) (No. 255/06) Lundbeck Ltd / Teva Pharmaceuticals Ltd 10 November 2006 The Scottish Medicines Consortium (SMC) has completed
WHAT IS STRESS? increased muscle tension increased heart rate increased breathing rate increase in alertness to the slightest touch or sound
EXAM STRESS WHAT IS STRESS? Stress is part of the body s natural response to a perceived threat. We all experience it from time to time. When we feel under threat, our bodies go into fight or flight response,
Your Safety System - a User s Guide.
1 Your Safety System - a User s Guide. Human beings are designed for safety SO: You have 2 settings: 1. An ordinary everyday setting And 2. An emergency threat setting. This gets the body ready for immediate
USF Mood & Anxiety Disorders Program
QUICK INVENTORY OF DEPRESSIVE SYMPTOMATOLOGY (SELF-REPORT)(QIDS-SR16) Please circle the one response to each item that best describes you for the past seven days. 1. Falling Asleep: 0 I never take longer
Early Treatment Options When to start, what with, and why?
September 2014 Early Treatment Options When to start, what with, and why? Dr Doug MacMahon FRCP (Lond. & Edin) dgmacmahon@hotmail.com Disclosure Dr MacMahon has received honoraria, fees for advisory boards,
Worries and Anxiety F O R K I D S. C o u n s e l l i n g D i r e c t o r y H a p p i f u l K i d s
Worries and Anxiety F O R K I D S C o u n s e l l i n g D i r e c t o r y H a p p i f u l K i d s Contents What is anxiety? Types of anxiety What does anxiety look like? Top tips for tackling worries Asking
Parkinson s Disease Prescribing Guidelines for use in Primary and Secondary Care
Parkinson's Disease Prescribing Guidelines for use in Primary and Secondary Care 2017 Parkinson s Disease Prescribing Guidelines for use in Primary and Secondary Care Document Description Document Type
Parkinson s Disease Duncan Gerry. 5/12/12 All drugs are poison
Parkinson s Disease Duncan Gerry 5/12/12 All drugs are poison Order of the Day Current and future of PD service in Hillingdon Case history highlighting the complexity of management, presentation and some
Drugs Affecting the Central Nervous System
Asst Prof Inam S Arif isamalhaj@yahoo.com Drugs Affecting the Central Nervous System Ass Efferent neurons in ANS Neurodegenerative Diseases Parkinson s Disease Multiple Sclerosis Alzheimer s Disease
Parkinson s disease stakeholder workshop notes
Parkinson s disease stakeholder workshop notes Discussion on the scope relates to version 5.3 which was circulated at the stakeholder workshop. Group 1 o What aspects of the previous guideline would you
Session 16: Manage Your Stress
Session 16: Manage Your Stress Stress is part of life. However, you can learn better ways to take care of yourself when faced with stress. Stress is not always bad. Some stress can make life interesting
Parkinson s Disease in 60 minutes. Dr. Claire Hinnell Movement Disorder Neurologist Director Movement Disorder Clinic JPOCSC
Parkinson s Disease in 60 minutes Dr. Claire Hinnell Movement Disorder Neurologist Director Movement Disorder Clinic JPOCSC S Plan of attack S What causes Parkinson s disease brief S Symptoms/Diagnostic
Section 4 - Dealing with Anxious Thinking
Section 4 - Dealing with Anxious Thinking How do we challenge our unhelpful thoughts? Anxiety may decrease if we closely examine how realistic and true our unhelpful/negative thoughts are. We may find
Brief Pain Inventory (Short Form)
Brief Pain Inventory (Short Form) Study ID# Hospital# Do not write above this line Date: Time: Name: Last First Middle Initial 1) Throughout our lives, most of us have had pain from time to time (such
Cannabis. Screening and Action Planning Toolkit. A toolkit for those who are concerned about their cannabis use and those who support them.
Cannabis Screening and Action Planning Toolkit A toolkit for those who are concerned about their cannabis use and those who support them. V1.: 015 About this tool: Cannabis dependency hasn t always been
BOOKLET ONE. Introduction to Behavioural Activation for Depression
BEHAVIOURAL ACTIVATION FOR DEPRESSION BOOKLET ONE Introduction to Behavioural Activation for Depression Contents Missing sources of wellbeing 2-3 Sources of misery 4-5 What we do when we feel down 6-7
SUPPLEMENT MATERIALS. Appendix A: Cleveland Global Quality of Life (CGQL) [0 being the WORST and 10 being the BEST]
![SUPPLEMENT MATERIALS. Appendix A: Cleveland Global Quality of Life (CGQL) [0 being the WORST and 10 being the BEST]](/thumbs/73/68207476.jpg "SUPPLEMENT MATERIALS. Appendix A: Cleveland Global Quality of Life (CGQL) [0 being the WORST and 10 being the BEST]")
SUPPLEMENT MATERIALS Appendix A: Cleveland Global Quality of Life (CGQL) [0 being the WORST and 10 being the BEST] Q1. Current Quality of Life: Circle one 6 7 8 9 10 Q2. Current Quality of Health: Circle
GENERAL INFORMATION PROFESSIONAL REFERRAL INFORMATION
SO THAT WE MAY BETTER SERVE YOU, PLEASE COMPLETE THE FOLLOWING FORM AND EITHER BRING THE COMPLETED FORM WITH YOU TO YOUR FIRST APPOINTEMNT OR SCAN IT AND EMAIL IT TO OFFICE, PRIOR TO YOUR APPOINTMENT LORRAINE@ANALIPSONMD.COM
handouts for women 1. Self-test for depression symptoms in pregnancy and postpartum Edinburgh postnatal depression scale (epds) 2
handouts for women 1. Self-test for depression symptoms in pregnancy and postpartum Edinburgh postnatal depression scale (epds) 2 2. The Cognitive-Behaviour Therapy model of depression 4 3. Goal setting
Drugs for Parkinson s Disease
This Clinical Resource gives subscribers additional insight related to the Recommendations published in July 2017 ~ Resource #330705 Drugs for Parkinson s Disease Parkinson s disease is characterized by
Session 7: Introduction to Pleasant Events and your Mood
Session 7: Introduction to Pleasant Events and your Mood Session Plan 1. Review of Planning for the Future 2. How Events Affect Your Mood 3. How to Identify Pleasant Events 4. Creating a List of Pleasant
Let s Sleep On It. Session Overview. Let s Sleep On It. Welcome and Introductions Presenter: Rita Piper, VP of Wellness
Let s Sleep On It Let s Sleep On It Welcome and Introductions Presenter: Rita Piper, VP of Wellness Session Overview Why Sleep is so Important Types of Sleep Common Sleep Disruptors Sleep Disorders Tips